Access this research
A Operational Excellence subscription is needed to access this content.
Please choose an option below
The emergence of COVID-19 vaccines with a 95% efficacy in clinical trials has provided businesses with new optimism that the end is in sight for the pandemic. This report provides corporate executives in operations, facilities and safety roles with an analysis of these announcements and a framework for business planning in 2021. To better understand what the vaccine developments mean for businesses, Verdantix analysed six promising vaccines and government rollout plans. An optimistic scenario will see the majority of the population inoculated by Q3 2021, but there are notable risks from manufacturing delays, distribution challenges and anti-vax campaigns. Verdantix recommends corporate leaders formulate plans across two time horizons; starting with the next 12 months with COVID-19 still circulating, followed by life beyond the pandemic, with the transition to the next normal.
Table of contents
COVID-19 Vaccine: How To Reset Your Business Planning For 2021 And Beyond
Vaccine Breakthroughs Create Hope Major Economies Will Contain The Pandemic In Q3 2021
Speed Of Inoculation By Region Will Depend On The Effectiveness Of Delivery Supply Chains
COVID-19 Will Require Ongoing Monitoring And Potential Further Interventions
Corporate Executives Need To Reset Their Business Plans To Look Beyond The Pandemic
Businesses Need To Manage COVID-19 Fatigue And Infection Flare-Ups During 2021
Businesses Need To Develop Plans For Success In The Next Normal
Table of figures
Figure 1. Six Promising Vaccines Are Emerging
Figure 2. Vaccine Distribution Plans For Australia, Canada, France, Germany, UK and US
Figure 3. Target Vaccine Rollout Timeline
Figure 4-1. COVID-19 Adaptations: Predictions For The Future (1/2)
Figure 4-2. COVID-19 Adaptations: Predictions For The Future (2/2)
Organisations mentioned
Apple,
AstraZeneca,
Audible,
BioNTech,
British Land,
GlaxoSmithKline (GSK),
H&M,
Headspace,
Johnson & Johnson (J&J),
Linklaters,
Moderna,
Novavax,
Oxford University,
Pfizer,
Sanofi,
Schneider Electric,
Sinovac,
Sprinklr,
TCS,
UK Department for Transport,
US Department of Defense,
Warner Bros
About the authors
Analyst
Hugo is a Technology Analyst in the Verdantix Operational Excellence practice. His research agenda focuses on covering connected worker technologies, best practices, market trends and growth strategies. Hugo joined Verdantix in 2020 having worked previously in public relations and earned media at Cision. He holds a bachelor’s degree in English from University College London.
Research Director
Susan leads the Verdantix Smart Buildings practice. Her current research agenda focuses on software solutions for real estate management including integrated workplace management systems and IoT platforms for buildings. Her research expertise also includes a broad range of energy management technologies and energy services. Susan has eight years of experience in technology research. She holds a MSc from the University of London in Sustainable Development.
Analyst
Chris is a Technology Analyst in the Verdantix EHS practice. His current research agenda focuses on digital mental health and wellbeing solutions. Chris joined Verdantix in 2020 and has previous experience at EY, where he specialised in robotic process automation (RPA). He holds an M.Eng. in Engineering Science from Oxford University with a concentration in machine learning and machine vision.